AIM ImmunoTech Inc. (AIM) Completes Dosing; Phase 2 Results Expected Q1 2027

AIM ImmunoTech completed Ampligen dosing in its Phase 2 DURIPANC study. Topline clinical benefit results are anticipated in Q1 2027; survival analyses are anticipated in Q3 2027.Material DetailsContext by AI AnalystThis is a mid-cycle clinical development update: dosing is complete, but efficacy da…